Table 1 Demographic data and clinical characteristics of all patients included in the study (n = 50)
From: Humoral and cellular response to SARS-CoV-2 BNT162b2 mRNA vaccine in hemodialysis patients
Age (years) | 69.4 ± 14.1 (25–90) |
Men/women | 31/19, 62 vs 38% |
Body Mass Index (BMI, kg/m2) | 26.1 ± 5.6 (13–44) |
Dialysis (months) | 65.1 ± 74.0 (5–470) |
Diabetes (n, %) | 23 (46) |
Nephrosclerosis (n, %) | 15 (30) |
Autosomal Dominant Polycystic Disease (n, %) | 4 (8) |
Chronic glomerulonephritis (n, %) | 8 (16) |
Vasculitis/anti-GBM-nephropathy (n, %) | 4 (8) |
Ongoing medication with CNIs (n, %) | 2 (4) |
Ongoing medication with MMF (n, %) | 1 (2) |
Previousa treatment with CNI (n, %) | 3 (6) |
Previousa treatment with Rituximab or Cyclophosphamide (n, %) | 5 (10) |
Current systemic steroid treatment (n, %) | 7 (14) |
Previous renal transplant (n, %) | 5 (10) |